Philips : HeartStart FR3 automated external defibrillator for professional responders treating victims of sudden cardiac arrest

November 14, 2011 – Royal Philips Electronics (NYSE: PHG, AEX: PHI) introduced Philips HeartStart FR3 automated external defibrillator (AED) in the U.S. for professional responders who treat victims of sudden cardiac arrest (SCA). As the smallest and lightest professional-grade AED among leading global manufacturers, the HeartStart FR3 is Philips’ most advanced professional-grade AED. The rugged and reliable HeartStart FR3 is designed to help make lifesaving faster and easier for professional responders. The FR3 requires a prescription for use in the United States, and must be used under medical direction.

SCA is one of the leading causes of death in the United States, claiming nearly 300,000 lives each year. Defibrillation is recognized as the only definitive treatment for ventricular fibrillation, the abnormal heart rhythm most often associated with SCA. While cardiopulmonary resuscitation (CPR) may help prolong the window of survival, CPR alone cannot restore a normal cardiac rhythm. After 10 minutes without defibrillation, few attempts to resuscitate an SCA victim are successful.

Recognizing that time-to-therapy matters, the HeartStart FR3 significantly reduces deployment time by eliminating steps to help responders start delivery of the right therapy – CPR or defibrillation – on the patient faster. The FR3 automatically powers on when the Philips HeartStart FR3 carry case is opened1. The device also features easy to access, pre-connected peel and place pads that do not require opening a foil pouch. These unique features help speed therapy delivery... Royal Philips Electronics' Press Release -

RegeneRx : Notice of Allowance on Two Cardiac-Related Patent Applications

November 17, 2011 — RegeneRx Receives Notice of Allowance on Two Cardiac-Related Patent Applications -

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.

The Australian patent is for the treatment or prevention of damage due to heart failure and will expire in July, 2026.

The Mexican patent is for the treatment or prevention of damage caused by increased blood flow in the myocardium, commonly called reperfusion injury. It will expire in January, 2026.

RegeneRx has similar patents pending in numerous other countries, including in the U.S., Asia and Europe... RegeneRx Biopharmaceuticals' Press Release -

STENTYS : Outstanding Interim Results of STENTYS International Clinical Study of 600 Heart Attack Patients

November 08, 2011 - PRINCETON, N.J. & PARIS - Lower rate of adverse events for STENTYS Self-Apposing™ Stent compared to reported results of conventional stents -

STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), disclosed today data on 600 patients from its ongoing “APPOSITION III” international clinical study who underwent an examination 30 day after treatment of a severe heart attack.

“With only 2.4% of patients experiencing a Major Adverse Cardiac Event (MACE) at 30 days in the latest patient cohort compared to rates of over 5% in published landmark trials with conventional stents, these remarkable preliminary clinical results could challenge the existing gold standard of treating AMI patients with balloon-expandable stents,” said study investigator Dr. Robert Jan van Geuns, M.D., Ph.D., Thorax Center at Erasmus Medical Center, Rotterdam, the Netherlands.

“We believe that these impressive clinical results confirm the Self-Apposing™ technology as the best solution for treating heart attack patients, and will contribute to increase its adoption in routine practice,” said Gonzague Issenmann, CEO and co-founder of STENTYS.

The STENTYS Self-Apposing™ Stent represents a major breakthrough: it solves the stent sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It “fits snugly” into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: malapposition... [PDF] STENTYS' Press Release -

Emboline : to Debut Game-Changing Embolic Protection Technology for Percutaneous Heart Valve Procedures in San Francisco Next Week

November 02, 2011 - Emboline CAP™: new approach to eliminating aortic embolic risk, providing Complete Accessible Protection™ from cardiac procedural-related emboli -

Emboline, Inc., an emerging medical device company, will debut its game-changing embolic protection devices for percutaneous heart valve repair and replacement in San Francisco next week.

The Company is initially focused on developing its novel Emboline CAP™ device; a next-generation system intended to provide complete protection of the arterial bed (both the cerebrals and the aortic lumen) utilizing a uniquely ported design that maintains tool access through the filter.

In addition, Emboline is also developing Emboliner™, a simple-to-use, low profile system for protection of the cerebral vessels alone... [PDF] Emboline's Press Release -